RxDoctor Payments Data

Christine Kempton, MD

Hematology · Atlanta, GANPI 1699882431

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (56.2%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Novo Nordisk at 56.2% of the total. Reporting peaked in 2020 at $26,691 and has fallen 91.1% since, to $2,370 in 2022.

$38,450in general payments, 2019–2025

Across 26 payments — averaging $1478.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$22K
  • Pfizer$5K
  • Takeda Pharmaceuticals U.S.A., Inc.$4K
  • F. Hoffmann-la Roche AG$4K
  • Sanofi US Services Inc.$3K
  • Spark Therapeutics, Inc.$1K
  • plus $211 from 1 others
$253,922in research payments, 2019–2025

Across 35 payments — averaging $7254.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$121K
  • Novo Nordisk$95K
  • F. Hoffmann-la Roche AG$20K
  • Bioverativ Therapeutics Inc.$11K
  • Takeda Pharmaceuticals U.S.A., Inc.$7K
  • Shire North American Group Inc$728

What the payments were for

  • Consulting fees$12,62633%
  • Speaking & faculty fees$3,90210%
  • Grants$21,62156%
  • Food & beverage$3011%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,450 in reported general payments places this provider in the 80th percentile of 27 hematology providers in Georgia.

See all hematology providers in Georgia

Medicare billing

Part B allowed, 2024
$9,240
Medicare patients
67
Services billed
90

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DopteletAvatrombopag Maleate16$332,415
EliquisApixaban147$136,908
XareltoRivaroxaban27$34,833
Enoxaparin Sodium13$3,598
Tranexamic Acid38$1,937
Morphine Sulfate ErMorphine Sulfate22$469
Oxycodone Hcl12$124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$4,770$136,908147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 27 hematology providers in Georgia.

Other hematology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →